Short answer
PUMA BIOTECHNOLOGY, INC. (PBYI) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $54M (down 32.4% year over year) with net income of $9M.
Q3 2025 key financials · XBRL
- Revenue
- $54M
- −32.4% YoY · +3.9% QoQ
- Net income
- $9M
- −56.5% YoY · +51.1% QoQ
- Operating margin
- 17.6%
- EPS (diluted)
- $0.17
- −58.5% YoY · +41.7% QoQ
Source: XBRL data from the PUMA BIOTECHNOLOGY, INC. (PBYI) Q3 2025 10-Q on SEC EDGAR. USD.
PUMA BIOTECHNOLOGY, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No risk-factors section provided in the submitted text
- No newly added risk or material risk-factor update identifiable
- Debt amendment disclosed through Eighth Amendment to Note Purchase Agreement dated October 6, 2025
- No specific regulatory, operational, competitive, market, liquidity, currency, or concentration risks disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PUMA BIOTECHNOLOGY, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.